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Abstract
Fragile X Tremor Ataxia Syndrome (FXTAS) is a common inherited neurodegenerative disorder caused by expansion of a
CGG trinucleotide repeat in the 59UTR of the fragile X syndrome (FXS) gene, FMR1. The expanded CGG repeat is thought to
induce toxicity as RNA, and in FXTAS patients mRNA levels for FMR1 are markedly increased. Despite the critical role of
FMR1 mRNA in disease pathogenesis, the basis for the increase in FMR1 mRNA expression is unknown. Here we show that
overexpressing any of three histone deacetylases (HDACs 3, 6, or 11) suppresses CGG repeat–induced neurodegeneration in
a Drosophila model of FXTAS. This suppression results from selective transcriptional repression of the CGG repeat–
containing transgene. These findings led us to evaluate the acetylation state of histones at the human FMR1 locus. In
patient-derived lymphoblasts and fibroblasts, we determined by chromatin immunoprecipitation that there is increased
acetylation of histones at the FMR1 locus in pre-mutation carriers compared to control or FXS derived cell lines. These
epigenetic changes correlate with elevated FMR1 mRNA expression in pre-mutation cell lines. Consistent with this finding,
histone acetyltransferase (HAT) inhibitors repress FMR1 mRNA expression to control levels in pre-mutation carrier cell lines
and extend lifespan in CGG repeat–expressing Drosophila. These findings support a disease model whereby the CGG repeat
expansion in FXTAS promotes chromatin remodeling in cis, which in turn increases expression of the toxic FMR1 mRNA.
Moreover, these results provide proof of principle that HAT inhibitors or HDAC activators might be used to selectively
repress transcription at the FMR1 locus.
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Introduction
Fragile X tremor ataxia syndrome (FXTAS) is a recently
described adult onset neurodegenerative disorder affecting ap-
proximately 1:3000 men and, less frequently, women over the age
of 50[1]. Affected individuals present with slowly progressive gait
ataxia, intention tremor, dementia, parkinsonism and neuropsy-
chiatric symptoms[2]. Pathologically, FXTAS patients develop
cerebellar and cortical atrophy with widespread neurodegenera-
tion. These gross pathologic changes are associated with
intranuclear ubiquitin-positive inclusions in neurons and astrocytes
of the cerebellum and cerebral cortex [3,4].
FXTAS results from pathological expansion of a CGG
trinucleotide repeat in the 59UTR of the FMR1 gene. Normal
repeats are less than 55 CGGs. Expansion to greater than 200
CGGs leads to transcriptional silencing of FMR1, causing Fragile
X Syndrome, a common inherited cause of mental retardation. By
contrast, FXTAS patients have modest expansions of between 55
and 200 CGG repeats. Intriguingly, this ‘‘pre-mutation’’ repeat
FMR1 mRNA is transcribed at 2–10 fold greater levels than in
control patients[5]. Because the expanded CGG repeat is
inefficiently translated, however, FMR protein (FMRP) levels are
normal or decreased in FXTAS patient-derived cell lines and in
animal models of the disorder [5–12].
Compelling evidence indicates that the expanded CGG repeat-
containing mRNA is the primary toxic species in FXTAS.
Expression of an expanded CGG repeat sequence in the 59UTR
of eGFP in human cell lines, Drosophila, or mouse Purkinje neurons
is sufficient to elicit toxicity[13–16]. A leading hypothesis for
disease pathogenesis is that FMR1 mRNA containing an
expanded CGG repeat binds to and sequesters important proteins
within nuclear inclusions, preventing them from performing their
normal functions [17–20].
Because FXTAS is thought to result from an RNA toxic gain-of-
function, the accumulation of increased FMR1 mRNA is likely an
important and proximal event in pathogenesis. However, work to
date has failed to identify the critical events driving this increase in
toxic mRNA. At least three non-exclusive mechanisms exist by
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which FMR1 mRNA accumulation could be altered. There could
be increased transcription at the FMR1 locus via a feedback loop
based on inefficient FMRP translation; presumably this would be
mediated via activation of a specific transcription factor cascade.
Evidence against this mechanism includes normal FMR1 mRNA
levels in a patient with a deleterious point mutation in FMRP[21]
and in patients with very large unmethylated CGG repeats who
translate little or no protein[22–24]. Alternatively, there could be
increased mRNA stability as a result of the altered secondary
structure of the FMR1 message. However, reports to date suggest
that excess transcription rather than altered mRNA stability is
critical to the accumulation of FMR1 mRNA [5,25]. A third
possibility, which to date has only been explored in vitro [26,27], is
that the premutation range CGG repeat itself could lead to
alterations in the local DNA and/or chromatin structure at the
FMR1 locus, stimulating increased basal transcription in cis.
Here we sought to determine the cause of increased transcrip-
tion in premutation carriers using Drosophila and cell-based model
systems. Our results provide evidence both that the expanded
CGG repeat enhances its own transcription in cis via alterations in
local chromatin structure and that this transcriptional augmenta-
tion may be pharmacologically modifiable.
Results
To better understand the pathophysiology of FXTAS, we
performed a screen of candidate genetic modifiers in an established
Drosophilamodel of CGG-repeat induced neurodegeneration, testing
known modifiers of other neurodegenerative disease models. As
previously described [13], expression of an expanded CGG repeat
sequence (90 CGGs with two AGG interruptions) in the 59
untranslated region of a heterologous transcript (enhanced Green
Fluorescent Protein, eGFP) in the fly eye leads to a rough eye
phenotype characterized by loss of pigmentation, omatidial
disorganization and abnormal eye bristle patterning (Figure 1E
versus Figure 1A)[13]. In lines expressing the transgene at higher
levels, the rough eye is more severe, with loss of normal oomatidia
formation and frank necrosis, especially when flies are reared at
higher temperatures (Figure 1B versus Figure 1A, 1E).
One known modifier of polyglutamine toxicity in Drosophila is
histone deacetylase 6 (dHDAC6). dHDAC6 is a Class 2B histone
deacetylase and one of only two Class 2 HDACs in Drosophila. It
has two human homologues: HDAC6 and HDAC10. HDAC6
deacetylates histones in vitro, and in Drosophila it acts on chromatin
to influence the expression of hundreds of genes[28]. However, in
mammalian systems it functions predominantly in the cytoplasm
where it deacetylates multiple substrates including a-tubulin,
cortactin and HSP90, and facilitates lysosomal degradation of
ubiquitinated proteins (see [29] for a recent review). Most relevant
to the current study, overexpression of dHDAC6 can rescue
polyglutamine induced neurodegeneration in an autophagy-
dependent manner in a Drosophila model [30].
We therefore were interested in assessing the influence of
dHDAC6 activity in a Drosophila model of expanded CGG-related
toxicity. Overexpression of dHDAC6 in FXTAS flies strongly
suppressed the rough eye phenotype (Figure 1C, quantified in
Figure 2G). Conversely, siRNA knockdown of dHDAC6
enhanced the CGG repeat induced phenotype (Figure 1F
compared to Figure 1E and 1G, note that the black material on
the eye in Figure 1F is eschar from necrosis). To test whether
suppression of the CGG rough eye phenotype by dHDAC6
required activation of autophagy pathways, we utilized a fly line
that co-expressed siRNA directed against the autophagy related
protein 12 (atg12), a protein required for appropriate autophagic
degradation of proteins. In contrast to dHDAC6 modification of
polyglutamine-related toxicity, siRNA knockdown of Atg12 had
no effect on suppression of the CGG repeat phenotype by
dHDAC6 (Figure 1D). Co-expression of a control protein, beta-
Gal, had no effect on the observed phenotype (Figure 1H) and
expression of eGFP at comparable protein levels but without a
CGG repeat in the mRNA had no intrinsic phenotype (Figure 1A).
Given that siRNA knockdown of autophagy pathways failed to
inhibit dHDAC6 dependent rescue of CGG repeat toxicity, we
hypothesized that dHDAC6 might be acting instead by altering
transcription of the (CGG)90-eGFP repeat containing transgene.
To test this idea, we first evaluated the effect of co-expression of
other HDACs on CGG repeat induced neurodegeneration.
Overexpression of either dHDAC3 (a major Drosophila class I
HDAC, Figure 2F) or dHDAC11 (a novel class IV HDAC,
Figure 2C and 2D, quantified in Figure 2G) also suppressed the
CGG repeat-dependent rough eye phenotype. Conversely, siRNA
directed against dHDAC11 exacerbated the CGG repeat
phenotype (Figure 2E compared to Figure 1E). This differs from
the observation in a Drosophila model of the polyglutamine disease
SBMA, in which the phenotype is not modified by altering
expression of dHDAC11 or dHDAC3 [30].
To further confirm a role for HDAC activity in modifying the
CGG repeat dependent phenotype, we reared flies expressing
eGFP or (CGG)90-eGFP on food containing either DMSO or the
broad spectrum HDAC inhibitor SAHA. At doses known to
suppress polyglutamine-induced neurodegeneration [31], the drug
had no effect on the normal eye phenotype in eGFP expressing
flies (Figure S1A). In contrast, (CGG)90-eGFP flies demonstrated a
significant exacerbation of the rough eye phenotype in the
presence of SAHA (Figure S1). In addition, SAHA partially
suppressed the phenotypic rescue seen in flies co-expressing
dHDAC6 and (CGG)90-eGFP (Figure S2), consistent with the
phenotypic rescue being dependent on deacetylase activity. The
lack of complete suppression of phenotypic rescue may be
explained by the relative insensitivity of dHDAC6 to broad
spectrum HDAC inhibitors [28,32].
Author Summary
FXTAS is a common inherited neurodegenerative disorder
resulting from accumulation of a toxic CGG repeat–
containing mRNA species in the brain. For unknown
reasons, expression of this toxic mRNA is markedly
increased in patients, and this increase is thought to
contribute to pathogenesis. Here we used a fruit fly model
of FXTAS and patient-derived cells to investigate the cause
of increased toxic RNA production in this disorder. We
identified histone deacetylases (HDACs) as genetic sup-
pressors of the neurodegenerative phenotype in Drosoph-
ila. These HDAC modifiers rescue the phenotype by
selectively lowering expression of the toxic mRNA. These
findings led us to evaluate the acetylation state of histones
at the human FMR1 locus. We found increases in histone
acetylation surrounding the CGG repeat in pre-mutation
carriers. These changes were associated with increased
transcription of FMR1 RNA. Moreover, we were able to
reverse these changes and lower production of the toxic
mRNA with drugs that inhibit histone acetylation. These
same drugs also extended lifespan in FXTAS model flies.
Taken together, our studies suggest a novel mechanism by
which FMR1 mRNA transcription is increased in FXTAS, and
they provide a proof of principle that such changes are
dynamic and modifiable by genetic or pharmacologic
alterations.
HDACs Suppress CGG Repeat-Induced Toxicity
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If overexpression of HDACs leads to phenotypic rescue by
reducing histone acetylation, the mRNA levels of the transgene
correspondingly would be expected to be lower in (CGG)90-eGFP
flies co-expressing HDACs. We therefore evaluated eGFP mRNA
levels in (CGG)90-eGFP flies at baseline and when HDACs were
modulated. Overexpression of HDAC3, HDAC6 or HDAC11
reduced (CGG)90-eGFP mRNA in Line 1 flies and HDAC6 or
HDAC11 reduced (CGG)90-eGFP mRNA in Line 2 flies as
measured by real-time semi-quantitative RT-PCR (Figure 3A). In
contrast, overexpression of dHDAC6 or dHDAC11 did not cause
changes in eGFP transcript levels in the absence of the CGG
repeat in two separate uas-eGFP fly lines with different
chromosomal insertion sites, consistent with previously published
results[33] (Figure 3B). Similarly, eGFP protein expression was
selectively decreased when (CGG)90-eGFP fly lines, but not eGFP
lines, co-expressed HDAC6 or 11 (Figure 3F–3H versus
Figure 3C–3E and additional data not shown). These findings
suggest that transcriptional repression of these transgenes is
dependent on the presence of the expanded CGG repeat
sequence. It is worth noting that these three HDAC proteins do
not alter expression of other transgenes, such as a polyglutamine-
containing androgen receptor in a Drosophila model of SBMA[30]
or uas-alpha synuclein in a Drosophila model of Parkinson’s
Disease[33]. Moreover, global HDAC inhibition or selective
siRNA knockdown of HDAC3 or 6 does not alter expression of
uas-HTT transgenes in a separate Drosophila model of polygluta-
mine disease [34].
These initial experiments were performed in Drosophila in the
absence of the full endogenous human promoter and chromatin
context. To extend our results to the human genomic context, we
analyzed patient-derived lymphoblast cell lines. First, we con-
firmed a previous report [5] that FMR1 mRNA levels are elevated
in lymphoblasts derived from patients with expanded (.80) CGG
repeats compared to lymphoblasts from normal controls (,45
CGG repeats) (Figure 4A, 4B). CGG repeat length correlated with
mRNA expression (r2 = 0.458, p = 0.01, Figure 4C). Two of the
pre-mutation lymphoblast cell lines (#C0051.004, (CGG)90, and
#C014.004, (CGG)91, a kind gift from Stephanie Sherman) were
derived from patients with clinically probable FXTAS. Four other
pre-mutation carrier cell lines were obtained from the Coriell cell
repository; clinical information on these cases is not available.
There was no difference in mRNA expression between the
clinically confirmed FXTAS cases and the Coriell derived lines
(Figure 4A and 4G). We therefore grouped data from all the pre-
mutation carrier cell lines for analysis. Individual profiles of each
cell line are presented in Figure S4.
Next we investigated chromatin modifications at the FMR1
locus surrounding the CGG repeat by performing chromatin
immunoprecipitation (ChIP) on lymphoblasts using antibodies that
recognize acetylated histones associated with active chroma-
tin[35]. In both control and pre-mutation carrier cell lines, we
observed specific pulldown of the FMR1 locus with antibodies
directed against either acetylated histone H3K9 or pan-acetylated
histone H4 compared to non-specific antibodies (Figure S3).
Figure 1. HDAC6 suppresses (CGG)90-eGFP–induced neurodegeneration by an autophagy independent mechanism. Expression of
eGFP alone in the fly eye with a gmr-GAL4 driver has no notable phenotype (A). When a CGG repeat is placed in the 59UTR of eGFP, a dose- and
temperature-dependent rough eye phenotype develops that is more severe in line 1 (B) than line 2 (E). The severe rough eye phenotype is
suppressed by co-expression of HDAC6(C). This phenotypic rescue by HDAC6 does not depend on an intact autophagy pathway, as siRNA-based
knockdown of atg12 does not prevent suppression (D). The mild rough eye phenotype seen in line 2 is synergistically enhanced by siRNA-based
knockdown of dHDAC6, producing a black necrotic eschar on portions of the eye(F). Of note, dHDAC6 knockdown induces a mild rough eye
phenotype when expressed alone (G). As a negative control, expression of Beta-Gal (lacZ) has no effect on the phenotype. (H). All images are
representative of .100 flies per genotype and at least two separate crosses. KD = knock down.
doi:10.1371/journal.pgen.1001240.g001
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Figure 2. HDAC3 and HDAC11 also suppress (CGG)90-eGFP mRNA–induced neurodegeneration. Co-expression of HDAC11, a class IV
HDAC and HDAC6 interacting partner, suppresses (CGG)90-eGFP induced neurodegeneration similarly to HDAC6 in either of two HDAC11-expressing
lines (C and D compared to A). Overexpression of HDAC11 alone had no phenotype (B). Lowering endogenous dHDAC11 by siRNA significantly
enhances (CGG)90-eGFP induced neurodegeneration (2E versus 1E). Similarly, overexpression of HDAC3, a class I HDAC, suppresses the (CGG)90-eGFP
phenotype (F). G) Quantitation of the phenotypes in Figure 1 and Figure 2. Analysis of ,20 flies per genotype demonstrates highly significant
alterations in the phenotype. * represents P,0.01 by a Students’ unpaired t-test. The lack of error bars on (CGG)90-eGFP line 1 and (CGG)90-eGFP line
2 co-expressed with siRNAs against HDAC6 and 11 reflect the fact that all observed flies had the most severe phenotype score.
doi:10.1371/journal.pgen.1001240.g002
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To investigate whether the expanded CGG repeat in pre-
mutation carriers influences the acetylation state of histones, we
compared the degree of pull down for regions of the FMR1 locus
directly surrounding the CGG repeat (the proximal FMR1
promoter and in the first exon of FMR1) by using semi-
quantitative real time PCR on DNA derived from the immuno-
precipitates. ChIP of acetylated histone H3K9 demonstrated
significantly elevated association of the FMR1 locus surrounding
the CGG repeats in pre-mutation patient derived cell lines
compared to control individuals with normal CGG repeat sizes
(Figure 4D). Similar results were obtained when ChIP was
performed with antibodies directed against pan-acetylated Histone
H4 (Figure 4E). As previously described, the FMR1 locus in a
single cell line derived from a Fragile X Syndrome patient with a
highly expanded and methylated CGG repeat showed little
association with acetylated histones (Figure 4D, 4E) [36–38]. As
a control, primers directed against the promoter region for
GAPDH, which is known to associate preferentially with
acetylated histones, did not detect any significant differences in
expression between control and expanded CGG repeat-containing
cell lines. The increased association of acetylated histones at both
histone H3K9 and histone H4 with the FMR1 locus correlated
with CGG repeat length (Figure 4F and Figure S5A, S5B, S5C,
S5D). This correlation was best modeled using a pooled analysis of
both histone markers and both PCR targets (r2 = 0.7337,
p = 0.004, Figure 4F). Similarly, the increased association with
acetylated histones correlated with FMR1 mRNA expression
(Figure 4G, r2 = 0.640, p = 0.001; correlations with individual
histone markers are shown in Figure S5E, S5F, S5G, S5H). No
differences were seen in histone acetylation at the FMR1 locus
between confirmed FXTAS cases and premutation cell lines whose
clinical information was not known (Figure 4G).
Although analysis of EBV-transformed lymphoblast cell lines
has been a mainstay of research related to chromatin changes
associated with Fragile X spectrum disorders, evidence suggests
that epigenetic changes in these cell lines do not always reflect the
chromatin state in the starting tissues [39–41]. We therefore
extended our results to patient derived fibroblast samples. Nine
previously published and characterized cell lines were obtained as
a kind gift from Dr Paul Hagerman: 3 from control patients
(repeat ranges from 22–31 CGGs), 3 from asymptomatic pre-
mutation carriers (67–81 CGG repeats), and 3 from clinically
probable FXTAS patients 97–122 CGG repeats, see materials and
methods for details) [42]. As previously described, FMR1 mRNA
expression was elevated in both pre-mutation carrier and FXTAS
patient-derived cell lines compared to controls, and FMR1 mRNA
expression correlated with CGG repeat length (Figure 5A,
5B)[42]. Consistent with our findings in lymphoblastoid cell lines,
pre-mutation carrier-derived fibroblasts demonstrated increased
association of acetylated histones with the FMR1 locus surround-
ing the CGG repeat sequence (Figure 5C, 5D). This association
was significant when all pre-mutation carriers were pooled for
analysis (p = 0.008 for both AcH3K9 and AcH4 results combined,
unpaired Students t-test). Comparisons of individual histone
markers were significant only at the AcH3K9 locus, perhaps
because of the low number of samples available for analysis.
Importantly, the changes in histone acetylation at the FMR1 locus
correlated with FMR1 mRNA expression (Figure 5F, r2 = 0.58,
p = 0.016) and CGG repeat length (Figure 5E, r2 = 0.53, p = 0.02).
Individual cell line ChIP results are shown in Figure S6. No
significant differences were seen in FMR1 mRNA expression or
Histone acetylation between FXTAS derived cell lines and
clinically unaffected premutation carriers, although the limited
Figure 3. HDAC over-expression suppresses the accumulation
of (CGG)90-eGFP mRNA. A) RT-PCR performed on total RNA isolated
from the heads of flies with the noted genotypes. eGFP mRNA
expression was normalized to18S RNA and expressed as fold change
compared to uas-eGFP (Chr2) x gmr-Gal4 alone. (CGG)90-eGFP transcript
levels for both line 1 and line 2 are significantly decreased when any of
3 classes of HDACs is co-expressed, compared to either line of (CGG)90-
eGFP crossed with the gmr-Gal4 driver line alone. B) In contrast, there
are no significant changes in eGFP mRNA levels when HDAC6 or
HDAC11 is co-expressed with either of 2 uas–eGFP lines with different
chromosomal insertion sites. Data represent the summary of 3
independent experiments with n.10 for each genotype. (C–H) eGFP
protein expression in fly lines was visualized by fluorescence. Co-
expression of HDAC6 (D) or HDAC11 (E) with eGFP leads to little or no
decrease in fluorescent signal. In contrast, eGFP protein expression in
(CGG)90-eGFP flies (F) is markedly reduced by co-expression of HDAC6
(G) or HDAC11 (H). * = P,0.01 versus (CGG)90-eGFP alone by a Students
unpaired t-test.
doi:10.1371/journal.pgen.1001240.g003
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Figure 4. Chromatin alterations at FMR1 locus in pre-mutation expansion carrier lymphoblasts. A) FMR1 mRNA expression by qRT-PCR
from 13 lymphoblastoid cell lines derived from male patients in fragile X families. FMR1 mRNA levels, normalized to actin mRNA, are expressed
relative to a control cell line included in all experiments ((CGG)41). White bars = control cell lines. Black bars = confirmed FXTAS cases. Light grey
bars = pre-mutation carriers whose clinical status is unknown. B) Correlation between CGG repeat size and FMR1 mRNA. Solid black dots = control
HDACs Suppress CGG Repeat-Induced Toxicity
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number of cell lines analyzed might preclude detection of a small
difference (Figure 5 and Figure S6).
Unlike some epigenetic modifications, histone acetylation and
deacetylation is relatively dynamic[43]. We therefore tested
whether we could selectively modify the histone acetylation status
of the FMR1 locus in pre-mutation carrier lymphoblasts. We
reasoned that if the homeostatic balance between histone
acetyltransferase (HAT) activity and HDAC activity could be
shifted by pharmacologically inhibiting HATs, then we might be
able to repress the increased FMR1 transcription seen in pre-
mutation carrier cell lines. To achieve this we first utilized the
broad spectrum HAT inhibitor garcinol[44]. Garcinol treatment
of pre-mutation carrier lymphoblasts for 24 hours resulted in
modestly reduced global histone acetylation as shown by western
blots detecting acetylated histone H3K9 (Figure 6A). To
determine whether this drug altered the acetylation status at the
FMR1 locus in FXTAS patient-derived cells, we performed ChIP
to acetylated histone H3K9 in cells treated for 24 hours with
DMSO or garcinol (10 mM). Garcinol treatment significantly
decreased the association of acetylated histone H3K9 with the
FMR1 locus in a probable FXTAS patient-derived cell line
(C014.004, (CGG)91)to a level similar to that of control cells
treated with DMSO (Figure 6B). This dose of drug has no
significant effects on histone acetylation at the FMR1 locus in
control cell lines.
FMR1 mRNA is known to have a relatively short half-life of
8 hours in lymphoblasts from both control and FXTAS derived
patients[5]. We therefore assessed what effect garcinol treatment
had on FMR1 mRNA levels in control and pre-mutation carrier
cell lines. Treatment with garcinol for 24 hours at multiple
different doses reduced FMR1 mRNA levels by over 50% in pre-
mutation CGG repeat cell lines (Figure 6C). Consistent with our
ChIP results, there was no effect on FMR1 mRNA levels in
control cell lines treated with garcinol.
To confirm these results, we tested the effects of another HAT
inhibitor, anacardic acid, on FMR1 mRNA expression. Anacardic
acid is a naturally derived compound from cashew nut oil, which
has been proposed as a natural anti-cancer drug[45]. As with
garcinol, treatment with anacardic acid led to only modest changes
in global histone acetylation by western blot (Figure 6A) but a
clear, dose-dependent reduction of elevated FMR1 mRNA to near
normal levels (Figure 6D). Significantly higher doses of anacardic
acid were required to suppress FMR1 mRNA expression in
control cell lines, despite the association of acetylated histones with
these loci (Figure 4C).
To evaluate whether these HAT inhibitor-induced changes in
FMR1 mRNA expression are transient or prolonged, we treated
lymphoblasts from one FXTAS patient (CGG91 repeats) with
10 mM garcinol for 24 hours, and then removed the garcinol for
48 hours. Compared to cells treated with DMSO alone for
72 hours, FMR1 mRNA expression in lymphoblasts transiently
treated with garcinol had largely returned to normal 48 hours
after removal of the HAT inhibitor (Figure S7). In contrast, FMR1
mRNA expression in cells treated for the entire 72 hours with
10 mM garcinol remained depressed (Figure S7). Given the known
lower translational efficiency of FMR1 mRNA containing an
expanded CGG repeat[7,22], we also evaluated whether FMRP
expression was affected by these drugs. Treatment with 10 mM
garcinol for 24 hours had no significant effects on FMRP
expression compared to cells treated with DMSO alone (Figure
S8D). However, with exposure to 10 mM garcinol for 72 hours,
FMRP expression decreased significantly (Figure S8D).
Because both Garcinol and Anacardic Acid are likely to have
broad spectrum effects on transcription, we evaluated the toxicity
of these drugs in patient derived lymphoblasts. At low doses of
drug (10 mM garcinol, 50 mM anacardic acid) delivered for
24 hours, the time course of most of these experiments, cell
viability was unchanged (Figure S8A). As previously published
[46], there was cytotoxicity and decreased cell viability evident
with higher doses and longer exposure times (Figure S8B).
Similarly, attempts to rear Drosophila on higher doses of these
drugs to test their efficacy in vivo demonstrated a dose-dependent
reduction in eclosion regardless of genotype, likely due to effects on
the chromatin alterations that occur during the transition from
larvae to adult flies (Figure S8C). However, if Drosophila were
exposed to these drugs after eclosion, they tolerated addition of
significantly higher doses (e.g. 400 mM garcinol) without signifi-
cant reductions in viability over at least 2 weeks (Figure 7A).
As a proof of principle, we therefore sought to assess whether
treatment of adult Drosophila with these drugs could affect their
lifespan. To accomplish this, we utilized the Geneswitch
conditional tissue-specific transgene system. This allows for
activation of the uas-(CGG)90 eGFP gene ubiquitously after
exposure of adult flies to RU-486[47]. In Drosophila transgenic for
the CGG expansion and co-expressed a ubiquitous GeneSwitch
driver (under the Tubulin promoter), there was very few fly deaths
over 2 weeks in the absence of RU-486 (Figure 7A, no drug).
When exposed to RU-486, however, these flies begin to die 3–4
days post drug for (CGG)90eGFP line 1, with 95% of flies dead by
day 7 (Figure 7A). For (CGG)90eGFP line 2, which has a less
severe phenotype when the transgene is expressed in the eye, flies
begin to die 5–6 days after exposure and all are dead by day 14
(Figure 7A). Flies expressing the Geneswitch driver alone had no
significant alterations in lifespan after exposure to RU-486
(viability = 90% after exposure to RU-486 alone for 14 days, data
not shown). The median survival and slope of the survival curves
was reliable over multiple trials (the data in Figure 7A represents 3
independent experiments and an n.30 flies/group, log rank test
for trend, x2 = 71.48, P,0.0001).
To test whether HAT inhibitors could extend the lifespan of
adult uas-(CGG)90 eGFP flies triggered to express the transgene
ubiquitously, 1–3 day-old adult animals were placed on food that
contained either RU-486 +DMSO or RU-486+ increasing doses
of Garcinol. As shown in Figure 7B, for (CGG)90eGFP line 1,
Garcinol led to a dose-dependent increase in survival that was
statistically significant at the highest two doses (Garcinol 100 mM
cell lines, stars = confirmed FXTAS cases, open circles = pre-mutation carriers whose clinical status is unknown. The central line is the linear best fit.
Curved dashed lines are 95% confidence intervals. The correlation is significant (Spearman correlation r2 = 0.515, p = 0.005). C) ChIP against acetylated
Histone H3K9 from all pre-mutation carriers (FXTAS and unknown clinical status, dark gray bars), controls (white bars), or FXS (spotted bars, 1 cell line)
patient-derived cell lines. PCR primers were targeted to the FMR1 promoter, the first exon of FMR1, or the GAPDH promoter as a control. D) ChIP
against acetylated Histone H4. For (C) and (D), ChIP DNA expression is normalized to input DNA and then graphed as fold change from a control cell
line included in all experiments. E) Correlation between CGG repeat length and H3/H4 acetylation status. Repeat length plotted against mean fold
change for association of the FMR1 locus with H3K9 or H4 acetylated histones. A combination of both markers at both the promoter and exon
provided the best fit model. F) Correlation between H3/H4 histone acetylation and FMR1 mRNA levels. G) Comparison of confirmed FXTAS cases
(black bars, n = 2) and pre-mutation lines whose clinical status is unknown (light grey bars, n = 4) with controls (white bars, n = 7). Dark grey bars =
Pooled data on all pre-mutation lines (n = 6). * = P,0.05 t-test vs controls.
doi:10.1371/journal.pgen.1001240.g004
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Figure 5. Chromatin alterations at the FMR1 locus in FXTAS patient derived fibroblasts. A) FMR1 mRNA expression in fibroblast cell lines
quantified by qRT-PCR, normalized to actin and expressed as fold change from the mean of 3 control cell lines. We used 3 control cell lines
(C1(CGG)31, C4(CGG)22 and C5(CGG)30) 3 asymptomatic pre-mutation carrier lines (P3(CGG)81, P4(CGG)70 and P5(CGG)67) and 3 cell lines from FXTAS
patients (F1(CGG)122, F2(CGG105 and F3(CGG)97). * = p,0.05 compared to controls. B) Correlation of CGG repeat length and FMR1 mRNA expression.
Black dots represent controls, open circles represent asymptomatic pre-mutation carriers, stars represent FXTAS patient-derived cell lines. Straight
line reflects best fit and curved lines represent 95% confidence intervals. The correlation is significant (r2 = 0.584, p = 0.016). C) ChIP performed on
fibroblasts using antibody to Acetylated H3K9. White bars represent primers directed against the FMR1 promoter, Gray bars against FMR1 exon 1.
Results are normalized to mean value of the control cell lines and expressed as fold change from this cell line. * = p,0.05 of averaged FMR1 levels
from the promoter and exon versus controls. D) ChIP performed on fibroblasts using an antibody directed against Acetylated Histone H4. Pooled
analysis grouping of all pre-mutation carrier-derived cell lines was significant for either AcH3K9 alone or a pooled analysis of both (AcH3K9, p = 0.02;
AcH4+AcH3K9, p = 0.008), unpaired Students t-test). E) Correlation of CGG repeat number to histone acetylation (r2 = 0.44, p = 0.05). F) Correlation of
FMR1 mRNA expression and histone acetylation at the FMR1 locus was significant (r2 = 0.582, p = 0.016). Data from individual cell line ChIP
experiments are shown in Figure S6.
doi:10.1371/journal.pgen.1001240.g005
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versus DMSO, Log Rank test, x2 = 2.92, p = 0.08; Garcinol
200 mM versus DMSO, Log Rank test, x2 = 16.89, p,0.0001;
Garcinol 400 mM versus DMSO, x2 = 10.98, p = 0.0003), with a
42% mean increase in lifespan on Garcinol 200 mM. Exposure to
Garcinol also significantly extended the lifespan of uas-
(CGG)90eGFP line 2, with 38% of adult Drosophila on 400 mM
Garcinol living past the pre-specified endpoint of the trial at 15
days (Figure 7C; Garcinol 100 mM versus DMSO, Log Rank test,
x2 = 5.52, p = 0.018; Garcinol 400 mM versus DMSO, x2 = 14.06,
p = 0.0002). Similarly, addition of 250 mM Anacardic acid to adult
flies also prolonged survival of uas-(CGG)90eGFP line 2 flies
(Figure 7D; 250 mMAA versus DMSO, Log Rank test, x2 = 20.86,
p,0.0001). In congruence with our earlier results showing
phenotypic rescue by dHDAC6, these changes in survival were
accompanied by a decrease in the expression of the (CGG)90eGFP
transgene (Figure 7E).
Discussion
Our results demonstrate that over-expression of three separate
histone deacetylases (HDACs 3, 6, or 11) suppress CGG-repeat
induced neurodegeneration in a Drosophila model of FXTAS. This
genetic suppression stems from selective transcriptional repression
of the transgene. These findings provided a clue to us that the
CGG repeat might induce alterations in local histone acetylation
at the FMR1 locus. To evaluate this in the human context, we
utilized patient-derived lymphoblasts and fibroblasts from pre-
mutation carriers and found that the FMR1 locus preferentially
associates with acetylated histones and this association correlates
with elevated FMR1 mRNA expression. Consistent with this
finding, histone acetyltransferase (HAT) inhibitors selectively
repress the association of acetylated histones with the expanded
CGG repeat locus and lower FMR1 mRNA expression to control
levels. These same HAT inhibitors are capable of extending the
lifespan of (CGG)90eGFP fly lines in which the gene is activated
ubiquitously in adulthood. These results provide evidence that
chromatin alterations associated with the expanded CGG repeat
sequence contribute to the elevated FMR1 mRNA levels in pre-
mutation expansion carriers. Importantly, the genetic and
pharmacologic approaches employed here suggest that these
chromatin alterations are modifiable, indicating that the enhanced
FMR1 mRNA expression in FXTAS patients could be a viable
therapeutic target.
In pre-mutation carriers, FMR1 mRNA levels are elevated 2–
10 fold; this finding has been noted in both FXTAS and
Figure 6. Correction of elevated FMR1 mRNA expression by
treatment with histone acetyltransferase inhibitors. A) Pre-
mutation carrier derived lymphoblastoid cell lines treated with DMSO,
10 mM garcinol, or 50 mM anacardic acid, for 24 hours are subjected to
western blot for Acetyl-Histone H3-K9. GAPDH is shown as a loading
control. B) Garcinol decreases chromatin acetylation at the FMR1 locus
selectively in pre-mutation carrier derived cells. Control (C0038.026;
(CGG)30) or FXTAS patient-derived lymphoblast cells (C014.004; (CGG)91)
were treated for 24 hours with either 10 mM garcinol or DMSO and
subjected to ChIP with acetyl-H3K9 antibodies. Data is expressed as fold
change from WT cells treated with DMSO and is a summary of 4
independent experiments. C) Garcinol selectively decreases FMR1 RNA
expression in pre-mutation carrier derived cells. The cell lines described
in (B) were treated with either DMSO or garcinol at the described doses
(in mM) for 24 hours, followed by RNA isolation and qRT-PCR. D)
Anacardic acid selectively decreases FMR1 mRNA expression in pre-
mutation carrier derived cells. The cell lines described in (B) were
treated with either DMSO or Anacardic acid at the specified doses (in
mM) for 24 hours and then processed as in (C). For both (C) and (D),
FMR1 mRNA levels were normalized to 18S RNA and expressed as fold
change from DMSO treated control cells. The data in (C) and (D) are a
summary of 3 independent experiments. For all panels, * represents a
p,0.05 on paired Students t-test compared to pre-mutation carrier
derived cells treated with DMSO.
doi:10.1371/journal.pgen.1001240.g006
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asymptomatic pre-mutation carrier lymphocytes and fibroblasts,
transformed lymphoblastoid cell lines, the brains of expanded
CGG-FMR1 knock-in mouse models, and FXTAS patient brains
[5,10,11,48]. For repeat expansions in the pre-mutation range, the
degree of elevation in mRNA expression generally correlates with
the size of the expansion. Several lines of evidence suggest that this
elevated mRNA level is due to increased transcription, rather than
altered stability, of FMR1 mRNA: 1) There are no changes in
RNA stability as measured by the rate of decline of FMR1 mRNA
levels after treatment with the transcriptional inhibitor actinomy-
Figure 7. HAT inhibitors extend lifespan in adult (CGG)90-eGFP flies. A) young (1–3 days post eclosion) adult (CGG)90eGFP line 1or line 2 flies
co-expressing a Tubulin Geneswitch driver were transferred to tubes containing normal fly food (blue line), food containing 400 mM Garcinol (red
line), or food containing RU486 to activate expression of the ubiquitous driver (Line 1, purple line, Line 2 green line). Data is expressed as % survival
over days and represents a summary of two independent experiments. B) For (CGG)90eGFP line 1, addition of Garcinol to the food containing RU486
led to a dose dependent increase in lifespan (purple = RU486+DMSO, blue= RU486+Gar 100 mM, orange= RU486+Gar 200 mM, red =RU486+Gar
400 mM, Log Rank test for trend, p,0.0001). C) Similarly, for (CGG)90eGFP line 2, addition of Garcinol to the food containing RU486 led to a dose
dependent increase in lifespan, with many flies at the highest dose surviving beyond the end of the study (green= RU486+DMSO, blue =RU486+Gar
200 mM, red =RU486+Gar 400 mM, Log Rank test (Mantel-Cox), p,0.0001). D) There was also a significant extension of lifespan with addition of
Anacardic Acid (250 mM) to the food of (CGG)90eGFP line 2 flies (green= RU486+DMSO, red =RU486+AA 250 mM, Log Rank test (Mantel-Cox),
p,0.0001). E) (CGG)90eGFP mRNA expression was significantly induced after feeding the flies food containing RU486 for 72 hours. This RU486
activated (CGG)90eGFP mRNA expression was suppressed by co-treatment with 400 mM Garcinol (* = paired Students t-test, p,0.01). Data presented
are the summary of two independent experiments with n = 10 flies per group for each study. (CGG)90eGFP mRNA is quantified in arbitrary units on
the y axis.
doi:10.1371/journal.pgen.1001240.g007
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cin[5]; 2) In nuclear run-on assays, mRNA stability does not differ
between controls and pre-mutation carriers[25]; and 3) FMR1
mRNA levels are similarly elevated in nuclear and cytosolic
fractions of lymphoblastoid cell lines, which would not be expected
if mRNA sequestration in nuclear inclusions were a major
contributor to increased mRNA accumulation[25].
What triggers this transcriptional activation? There are at least
two non-exclusive possibilities. First, because the CGG repeat
expansion impairs translation of FMR1 mRNA into protein, the
increase could result from a feedback loop driven by lower levels of
the Fragile X Mental Retardation Protein, FMRP. Alternatively,
the increase in transcription could result from intrinsic changes in
local chromatin structure induced by the expanded CGG/CCG
repeat itself [49]. In support of this latter hypothesis, pre-mutation
expanded non-methylated CGG/CCG tracts exclude nucleo-
somes in vitro and preferentially associate with acetylated rather
than non-acetylated histones, which would be predicted to
enhance basal transcriptional activity [26,27]. Moreover, recent
genome-wide evidence suggests that non-methylated CpG islands
are predominantly associated with markers of active chromatin,
including acetylated histones[50]. Consistent with a primary effect
of the CGG expansion in cis on transcription, we observed
increased (CGG)90-eGFP mRNA expression in two Drosophila lines
compared to control eGFP mRNA expression with the same
promoter and driver (Figure 3A). Although these findings could be
artifacts explained by insertion site variation, we suggest instead
that they may reflect intrinsic effects of the CGG repeat on DNA
structure that influence transcription efficiency.
Extensive work has characterized the regulation of basal and
activity-dependent transcription of the FMR1 gene with a normal
sized CGG repeat versus the fully expanded repeat of Fragile X
Mental Retardation (FXS). In most FXS patients both an
upstream CpG island and the expanded CGG/CCG repeat are
hypermethylated[51,52]. This hypermethylation drives the chro-
matin state at this locus from euchromatin to heterochromatin,
and the H3 and H4 histones associated with the FMR1 promoter
and 59UTR become hypoacetylated [36–38]. This combination of
hypermethylation and heterochromatin results in transcriptional
silencing of the FMR1 gene and the symptoms of FXS. Treatment
of FXS patient lymphoblasts with general histone deacetylase
(HDAC) inhibitors partially reverses transcriptional silencing in
lymphoblastoid cell lines[53] and treatment of FXS patients with
valproic acid, an antiepileptic and mood stabilizing drug with
HDAC inhibitor activity, has produced promising preliminary
results [54]. However, full reactivation of the gene also usually
requires demethylation of the DNA. Previous work has also
characterized chromatin changes in fibroblasts and lymphoblasts
derived from unmethylated full mutation(.200 CGG repeats)
patients [22,23,55]. In these cases, FMR1 mRNA expression is
close to normal but protein expression remains very low or absent
because of translational inefficiency. In unmethylated full mutation
patient-derived cells, histone H3/H4 acetylation remained
significantly depressed compared to controls and remains closer
to methylated full mutation carrier levels despite close to normal
FMR1 transcription[22,23,55]. However, histone methylation and
demethylation events are more predictive of transcriptional
activity in these cell lines.
Our results concur with these previously published studies and
provide new information about the chromatin state in FXTAS
patient-derived cells. In lymphoblasts and fibroblasts with an
expanded non-methylated pre-mutation length CGG repeat, we
observe an increase in acetylated H3 and H4 histones at the FMR1
locus surrounding the CGG repeat. In light of previously
published data, our results suggest that the modestly expanded
FXTAS repeat sequence alters chromatin structure in cis, largely
through preferential association with acetylated histones, which in
turn promote transcription at the FMR1 locus, driving up FMR1
mRNA levels and potentially exacerbating RNA mediated
toxicity. It remains unclear, however, why a pre-mutation repeat
expansion behaves differently than an unmethylated full mutation
length repeat expansion[22]. Further, we have not yet analyzed
other potential chromatin changes at the FMR1 locus such as
histone methylation, which might contribute to transcriptional
regulation in pre-mutation carriers. Future studies will be needed
to address these questions.
Our findings do not exclude an independent contribution to
elevated FMR1 transcription from transcription factor activation
in response to inefficient FMRP translation. In both pre-mutation
carriers and full expansion unmethylated Fragile X cases, the
CGG repeat interferes with translation by altering the loading of
the FMR1 mRNA onto polysomes[7,8,22,24] Several lines of
evidence, however, suggest that transcription factor activation is
not the dominant cause of elevated FMR1 levels. Perhaps most
convincing are data from a fragile X syndrome patient with a
point mutation that encodes a nonfunctioning but stable FMRP.
In this patient, who has a normal CGG repeat, FMR1 mRNA
levels are normal [56]. Similarly, a knock-in model of this same
mutation into the FMR1 locus in mice recapitulates many features
of the Fragile X phenotype but FMR1 mRNA levels were not
altered[21]. In addition, FMR1 levels are elevated in most tissues
in FXTAS patients and CGG repeat expressing mice, despite
probable compensatory mechanisms related to FXR1 and FXR2
functions in these tissues and the lack of a significant tissue
phenotype in FXS patients [3,10,11,57]; it is unclear why there
would be a strong feedback trigger for transcription of FMR1 in
tissues where its function is not clearly essential. However, the role
of decreased FMRP translational inefficiency in FMR1 pre-
mutation transcription will need to be addressed empirically in
future studies.
Pre-mutation carriers demonstrate a reduced penetrance for
FXTAS. It is estimated that only 40% of pre-mutation carrier
males will manifest symptoms prior to death[1,58], but what
features drive the penetrance of FXTAS remain unknown.
Epigenetic changes are one possible mechanism. This study was
not designed or powered to assess differences between asymptom-
atic pre-mutation carriers and FXTAS patients. However, we did
not observe any significant differences in FMR1 mRNA
expression or histone acetylation patterns of asymptomatic pre-
mutation carriers versus FXTAS patient derived fibroblasts. What
little differences were seen are largely attributable to larger CGG
repeat expansions in the FXTAS patient derived cell lines. Larger
studies utilizing pathology confirmed FXTAS cases and controls
will be required to fully answer this question. Evaluating what
factors influence the incomplete penetrance in this disorder,
including further analysis of the role played by the antisense
message that is transcribed through the CGG/CCG repeat
[59,60], is an area ripe for further research. In addition, future
work will be needed to more critically address how this CGG/
CCG repeat can influence transcription. For example, is the
presence of the repeat alone adequate to induce alterations in
histone acetylation and transcriptional activation or is the
surrounding FMR1 59UTR important in the ability of the CGG
repeat to influence transcription? Does the CGG repeat have to be
transcribed to cause these alterations? And what role does
antisense CCG repeat transcription play in both transcriptional
and post-transcriptional regulation of FMR1?
HDAC inhibition has emerged as a potential therapeutic
strategy in numerous neurodegenerative diseases, including
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polyglutamine disorders [31,34]. In contrast, our work identifies
three different classes of HDACs as potential suppressors of CGG
repeat induced neurodegeneration. Consistent with this finding,
treatment of patient lymphoblasts with Histone Acetyltransferase
(HAT) inhibitors suppressed FMR1 mRNA expression selectively
in pre-mutation carrier derived cells. A few caveats need to be
addressed to fully understand these findings. Although the tested
HDACs likely rescue the phenotype by suppressing CGG repeat-
dependent transgene transcription, some of their activity could
reflect other effects, including altering transcription of other genes
critical to CGG repeat-dependent toxicity. HDAC6 in particular
has cytoplasmic functions linked to autophagy that could mitigate
the CGG repeat neurodegenerative phenotype. A major role for
autophagy in the suppression we observed is unlikely, however,
given that siRNA directed against a critical component of the
autophagy pathway has no effect on CGG repeat-dependent
phenotypic rescue by dHDAC6 (Figure 1). In contrast, this same
siRNA prevents dHDAC6-dependent rescue of a polyglutamine
phenotype ([30] and data not shown). It is worth noting that
dHDAC6 did not suppress transcription of eGFP alone at two
different insertion sites or of a polyglutamine disease gene
(androgen receptor with 52 or 120 CAG repeats) in Drosophila
[30], suggesting that the HDAC-mediated transcriptional repres-
sion we observe may be a CGG repeat-specific event.
We demonstrate that two different histone acetyltransferase
inhibitors, anacardic acid and garcinol, can lower FMR1 mRNA
levels in pre-mutation carrier derived lymphoblasts. For garcinol,
this suppression of FMR1 mRNA expression correlates with
decreased association of acetylated histones with the FMR1 locus.
Intriguingly, the effects of these drugs, at least at lower doses, seem
to be somewhat selective for the expanded CGG repeat effects in
the FMR1 locus, as the effects on chromatin structure and FMR1
mRNA expression are less pronounced in control cell lines and the
global acetylation state of histones in the cells are not dramatically
altered. These data support a model whereby the histone
acetylation state and thus the chromatin structure at the FMR1
locus is more dynamic in the setting of an expanded CGG repeat.
As with the effects of HDAC overexpression in the Drosophila
model, the effects of HAT inhibitors on FMR1 levels in
lymphoblasts may be pleotropic. Future work should better
delineate how these drugs achieve a reduction of FMR1 levels.
Regarding the potential use of HAT inhibitors as therapeutic
agents, both garcinol and anacardic acid are naturally occurring
chemicals that have been used in humans as homeopathic agents.
In addition, both have been proposed as possible anti-cancer
agents clinically [61,62]. However, these drugs lead to a global
repression of transcription and cytotoxicity in dividing cells at
doses necessary to achieve significant histone acetyltransferase
inhibition (see Figure S8 and [44,61,63,64]). Thus, they are likely
to be too toxic with significant non-specific off target effects to
achieve transcriptional repression of a single gene in patients.
Consistent with this, we were unable to suppress CGG-repeat
induced neurodegeneration in our Drosophila model with HAT
inhibitors delivered prior to eclosion due to significant non-specific
toxicity (Figure S8 and data not shown). Even if FMR1
transcription can be efficiently and selectively targeted, a balance
will need to be achieved between lowering FMR1 mRNA to a
non-toxic level while maintaining FMRP expression, given the
known phenotype associated with the loss of FMRP (Fragile X
mental retardation). Consistent with this concern, we see a
significant reduction in FMRP levels in pre-mutation-carrier
lymphoblasts after treatment with Garcinol for 72 hours (Figure
S8D). Thus, our findings to date are best viewed as a proof of
principal that FMR1 transcription in pre-mutation carrier cells are
amenable to pharmacologic and genetic manipulation, rather than
indicative that these agents should serve as a basis for therapeutic
development. Our results also raise the potential concern that
drugs that display activity as HDAC inhibitors might be harmful
in FXTAS patients. For example, Valproic acid, a drug that may
be considered for patients with neuropsychiatric symptoms or
seizures, is known to have HDAC inhibitor activity. This
theoretical risk may warrant investigation in FXTAS patients.
In summary, we provide evidence that HDAC expression in vivo
or pharmacologic treatment with HAT inhibitors in patient cells
can correct the transcriptional upregulation associated with pre-
mutation length expanded CGG repeat sequences. Our data
support a model whereby the expanded CGG repeat sequence in
the FMR1 gene in FXTAS patients alters local chromatin structure
in cis to favor increased FMR1 transcription. It remains unknown
how the expanded repeat drives such changes in chromatin, but in
vitro data suggest it may stem from changes in secondary DNA
structure that discourage association with de-acetylated histones
and nucleosomes[26]. These changes in DNA structure then drive
FMR1 overexpression in FXTAS and contribute to neurodegen-
eration. Importantly, our results suggest that these alterations in
chromatin structure at the FMR1 locus are dynamic and
modifiable, such that various genetic and pharmacologic manip-
ulations of the state of histone acetylation at and near the CGG
repeat can change the level of transcription in human cells and in
animal models. Our findings underscore the importance of
developing more specific modifiers of FMR1 transcription with
the long term goal of developing preventive therapy for FXTAS
patients.
Materials and Methods
Fly stocks
All Drosophila experiments were performed on standard food in
25uC incubators unless otherwise noted. Uas-(CGG)90eGFP lines
1 and 2 (designated lines BD and BC, respectively) were a kind gift
from Peng Jin at the University of Emory and have been
previously described [13,18,19]. Stability of the CGG repeat was
confirmed by PCR and sequencing using C and F primers as
described previously [13,65–67]. Uas-dHDAC6L #13 and UAS-
dHDAC6kd flies have been previously described and character-
ized [30]. UAS-HDAC11kd #1B3 and UAS-dHDAC6KD were
obtained as a kind gift from Dan Garza at Novartis Pharmaceu-
ticals. Tub-Gal4, Gmr-GAL4, Uas-eGFP and UAS-LacZ fly lines
were obtained from the Bloomington Drosophila Stock Center
(Bloomington, IN).
The cDNA for Drosophila HDAC3 and HDAC6 were amplified
from the expressed sequence tag (EST) clones LD23745 and
LD43531, respectively. The coding region for Drosophila HDAC11
was generated by positional cloning from EST clone CG31119-
RA. Primers were created to insert 59 Kpn I and 39 Xba I
restriction sites and the constructs were ligated into the pAc5.1/V5
vector (Invitrogen, Carlsbad, CA) as previously described [28].
Primers were then generated to introduce Spe I at the 59 end just
upstream of the Kpn I site and Avr II at the 39 end of the dHDAC
constructs maintaining the V5 tag, 6xHIS, stop codon and the
SV40 pA sites from the pAc5.1/V5 vector and was subcloned into
a pINDY6 vector [68] cis to the yeast upstream activating
sequence (UAS). The pINDY6 vector containing the dHDACs
was used to generate transgenic fly lines using standard germ-line
transformation by Genetic Services (Cambridge, MA). The
dHDAC expression was activated in genetic crosses trans to the
yeast GAL4 transcription factor, which was in turn regulated by
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the eye-specific promoter GMR upstream of the yeast GAL4
cDNA.
Eye images
Eye phenotypes of 1–2 day-old anesthetized flies were evaluated
with a Leica MZ APO stereomicroscope and photographed with a
Leica DFC320 digital camera as previously described [30]. For
each genotype and condition, at least 100 flies were evaluated. For
fluorescent images of Drosophila heads to evaluate eGFP expression,
animals were anesthetized with CO2, decapitated, and immedi-
ately imaged on a glass coverslip by epifluorescence on an inverted
Olympus IX71 microscope. All images were taken at the same
exposure. Images were processed using Slidebook 4.0 software and
subtracted for background auto-fluorescence based on images of
non-transgenic flies. Images are 10x in coronal orientation. For
quantitation of the severity of the eye phenotypes, a degeneration
scale was used as previously described [30]. Briefly, flies were given
a score between 0 and 10 on the following scale: 1 point for
extranumerary bristles, 1 point for abnormal bristle orientation, 1
point for oomatidial fusion, 1 point for oomatidial pitting, 1 point
for retinal collapse. In addition, 1 point was added if more than
5% of the eye was affected, 4 points was added if more than 50%
of the eye was affected. For quantitation, at least 20 flies per group
were utilized.
SEM
SEM samples were processed as previously described [30].
Briefly, flies were collected and fixed in 2.5% glutaraldehyde
(EMS) in PBS and post-fixed for 15–30 minutes in 1.5% osmium
tetroxide (Stevens Metallurgical) in PBS. Samples were then
dehydrated in ethanol, immersed in hexamethyldisilazane (Poly-
sciences Inc.) and dried in a desiccator for three days. Specimens
were then coated with gold:palladium using a Denton DV-503
vacuum evaporator, and analyzed using an AMRAY 1820D
scanning electron microscope.
RT-PCR
Semi-quantitative RT-PCR analysis in cells and Drosophila was
performed as previously described [30,69]. Briefly, flies of the
specified genotypes were decapitated under anesthesia and the
heads were flash frozen on dry ice. After crushing the heads with a
pipette tip, total RNA was extracted using Trizol reagent
(Invitrogen, San Diego, CA) according to manufacturer’s proto-
cols. Lymphoblastoid Cell lines were homogenized directly in
Trizol prior to extraction. Following spectrophotometric quanti-
fication, 1 mg of total RNA was reverse-transcribed (iScript cDNA
Synthesis Kit; BioRad, Hercules, CA) and the resulting cDNA
subjected to quantitative real-time PCR analysis with gene specific
primers [38] as follows: eGFP: (Fwd: CTGCTGCCCGA-
CAACCA; Rev: GAACTCCAGCAGGACCATGTG), FMR1:
(Fwd: CCGAACAGATAATCGTCCACG; Rev: ACGCTGT-
CTGGCTTTTCCTTC), 18S Fly: (Fwd: CGGCTACCACATC-
CAAGGAA; Rev: GCTGGAATTACCGCGGCT), 18SHum:
(Fwd:CAGCCACCCGAGATTGAGCA; Rev:TAGTAGCGAC-
GGGCGGTGTG), b˜Actin: (Fwd: GGCATCCTCACCCTG-
AACTA; Rev:AGAGGCGTACAGGGATAGCA), GAPDH:
(Fwd: AGAAGGCTGGGGCTCATTTG Rev: AGGGGC-
CATCCACAGTCTTC).
PCR analysis was performed using the iQ SYBR Green
Supermix in a myiQ Single Color RTPCR system (BioRad). All
runs included a standard dilution curve representing at least 10x
and 0.01X the RNA concentration utilized for all primer sets to
insure linearity. Further, equivalent efficiency of individual primer
sets was confirmed prior to data analysis. For Drosophila, the levels
of (CGG)90-eGFP mRNA were normalized to those of 18S RNA
or GAPDH mRNA for each sample run and expressed as a ratio
of levels found UAS-eGFP lines (fold control expression). For
lymphoblast derived mRNA quantitation, levels of FMR1 mRNA
were normalized to actin RNA or 18S RNA and expressed as a
ratio of mean expression of normal repeat length cell lines (fold
control expression). All samples were run in triplicate and all data
represent at least three independent experiments.
Lymphoblastoid cell lines
Three cell lines were obtained as a kind gift from Stephanie
Sherman at Emory University. Their brief clinical history is below:
1. C0140.004 (CGG 91), Definite FXTAS; 62 y.o. man with
onset of symptoms around age 50, Middle cerebellar Peduncle
(MCP) sign on MRI, postural kinetic tremor early, developed
gait ataxia, cerebellar tremor, voice tremor and head
titubation; no nystagmus or parkinsonian features.
2. C0051.004, (CGG 90) Definite FXTAS; Onset at 59, postural
tremor with mild gait imbalance. MCP sign on MRI;
3. C0038.026, asymptomatic male with 30 CGG repeats.
All other lymphoblastoid cell lines were obtained from the
Coriell Cell Repository (Coriell, Camden, NJ).
1. GM09237, symptomatic FXS male with .900 CGG repeats.
2. GM06891, 29YO male with 118 CGG repeats, clinical status
for FXTAS unknown.
3. GM06892, 84YO male with 93 CGG repeats, clinical status for
FXTAS unknown.
4. GM06895, 55YO male with 23 CGG repeats; related to 6891
and 6892, clinical status unknown.
5. GM20244, 43 YO male with 41 CGG repeats, clinical status
unknown.
Repeat size was confirmed by PCR for all lines except for the
FXS patient line, as previously described using C and F primers
[65,67]. Cells were grown in RPMI 1640 media with Glutamine
pre-added (Invitrogen) and 12% fetal bovine serum plus antibiotics
as previously described[12].
Fibroblast cell lines
Nine fibroblast cell lines were obtained as a kind gift from Dr
Paul Hagerman and colleagues (University of California at Davis).
The clinical state of these patients has been described previously
and all cell lines were obtained from males [42]. Nomenclature
used follows that used in the publication where these lines were
first published [42]. Briefly, there are three control lines: C1
(CGG31), C4 (CGG22) and C5 (CGG30). There are three cell
lines from asymptomatic pre-mutation carriers (all at least 68 years
old): P3 (CGG81), P4 (CGG70) and P5 (CGG67). Lastly, there are
three cell lines from patients with clinically definite FXTAS based
on established criteria[70]: F1 (CGG122), F2 (CGG105) and F3
(CGG97). Fibroblasts were cultured and maintained as previously
described[42] and repeat size was confirmed by PCR for all lines
using C and F primers [65,67].
Chromatin immunoprecipitation
Formaldehyde Cross linking ChIP was performed according to
previously published commercial protocols using a ChIP kit
(Millipore, Temecula, CA) [71]. Antibodies to Histone H3 acetyl
K9 (ab10812, Abcam, Cambridge, MA), Acetyl Histone H4
(abCS200571, Millipore), or rabbit IgG (Millipore) were used to
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immunoprecipitate the DNA/protein complexes overnight. After
reversal of crosslinks and DNA isolation, real time PCR was
conducted on equal concentrations of input and IP derived DNA
in triplicate. Primers used against the FMR1 promoter and exon1
were previously published [38]. Control primers to human
GAPDH optimized for ChIP were obtained commercially
(Millipore). FMR1 DNA quantity from IP was normalized to
input FMR1 DNA. This number was then re-normalized to the
mean of the control cell lines and expressed as fold change from
this mean. For both selective antibodies, IP qPCR was similar to
input and .10x of ChIP with rabbit serum or non-specific
antibodies (e.g. Beta-gal) for both FMR1 and GAPDH primers
(Figure S3). PCR primers targeted within 100 bp upstream or
downstream of the CGG repeat showed similar results, but with
altered efficiency due to high GC content, complicating quanti-
fication (data not shown).
Drug treatment of cell lines
Anacardic Acid was obtained from Calbiochem and Garcinol
was obtained from Sigma. All drugs were dissolved in DMSO.
Cells were treated for 24 or 72 hours (Garcinol 10, 20, or 50 mM
or Anacardic Acid at 10, 50, 200, or 500 mM) with drug added
directly to the culture media. Both 18S RNA and actin were used
as internal controls for qRT-PCR experiments. FMR1 mRNA
expression was normalized to 18S RNA in all drug experiments
rather than actin because at the highest doses of both drugs, there
were alterations in actin, GAPDH and c-myc mRNA levels (data
not shown).
Cell viability and cytotoxicity assays
Determination of cell viability and cytotoxicity was performed
using a MultiTox-Glo Multiplex Cytoxicity Assay kit from
Promega (Madison, WI, USA) according to the manufacturers’
protocol. Additional viability assays were done using trypan blue
exclusion with similar results.
Lifespan studies in Drosophila
RU-486(Sigma) or Vehicle(Ethanol) was added to standard fly
food at a final concentration of 200 mM as previously described
[72]. Uas-(CGG)90eGFP line 1 and line 2 fly lines were crossed
with flies expressing a Gene-Switch Tubulin-Gal4 driver (Tub5, a
kind gift from Scott Pletcher at the University of Michigan). At 0-3
days post eclosion, flies of the specified genotype were switched to
food containing drug or vehicle at 25C at 60% humidity. Viability
was assessed daily for 15 days or until all flies were dead,
whichever came first. This latter time point was chosen because of
concerns over the stability of RU-486 and HAT inhibitors over
time.
For drug studies, Garcinol (from a stock solution of 100 mM),
Anacardic acid (stock solution of 250 mM) at various concentra-
tions or an equal volume of vehicle (DMSO) were added to food
containing RU-486 as described above. Different volumes of
DMSO had the same viability as RU-486 alone, so these results
were pooled for statistical analysis. Data in Figure 7 represents a
summary of at least 3 independent experiments with all results
pooled.
For viability assays done pre-eclosion, uas-eGFP/CyO (Chr 2)
or uas-(CGG)90eGFP/CyO line 1 and line 2 fly lines (Chr 2) were
crossed with flies expressing a tubulin-Gal4 driver (Chr 3).
Viability was assessed by determining the ratio of progeny
carrying the balancer chromosome (CyO) to those carrying
the UAS-transgene. Data are representative of at least 4
experiments.
Western blotting
Western blotting to FMRP was performed as previously
described [73]. Briefly, cell lysates were lysed in RIPA buffer,
sonicated, and quantified by the method of Bradford. Equal
protein amounts were then boiled in 2x Laemmeli buffer and run
on a 12% SDS polyacrylamide gel. After transfer to PVDF
membrane at 36 amps for 1.5 hours at 4C, the blots were
incubated with antibodies to FMRP (Millipore 1:1000 O/N at 4C)
and GAPDH (Santa Cruz Biotechnology, used at 1:1000 O/N at
4C). Images from westerns are representative of at least 2
independent experiments with similar results.
Statistical analysis
For all graphs, error bars represent Standard error of the mean
calculated in Microsoft Excel. For comparisons of single groups, a
Student’s two sided T-Test was performed. For drug studies in
lymphoblast cell lines, these were done as a paired T-Test. For all
others, unpaired T-tests were performed.
Other statistical analyses were performed using GraphPad
Prism. For correlation analysis, data are presented as the best fit
curve with 95% confidence intervals. r2 (coefficient of determina-
tion) is included as a measurement of variance explained by the
selected variable. An F test was performed to determine statistical
significance. For comparisons to CGG repeat length, a Spearman
correlation was used to account for the non-parametric distribu-
tion of repeat lengths in our samples. All other comparisons
utilized a Pearson correlation. For survival analysis, a Log-rank
(Mantel-Cox) test or a Log-rank test for Trend was performed.
Flies surviving past the specified end of the study (15 days) were
assigned a survival time of 15 days for statistical purposes.
Supporting Information
Figure S1 The HDAC inhibitor SAHA exacerbates CGG
repeat dependent neurodegeneration. Scanning electron micros-
copy (A–D) or light microscopy (E–G) images were obtained from
flies expressing eGFP (A) or (CGG)90-eGFP line I (B–G). Flies were
reared at 25C in standard fly food containing either DMSO (B,E)
or the broad spectrum HDAC inhibitor SAHA at 150 mM (C, F)
or 300 mM (A,D,G). Images are representative of greater than 25
flies per treatment group.
Found at: doi:10.1371/journal.pgen.1001240.s001 (3.86 MB TIF)
Figure S2 The HDAC inhibitor SAHA partially suppresses
rescue by dHDAC6 of CGG repeat dependent neurodegenera-
tion. Representative SEM images from drosophila co-expressing
(CGG)90-eGFP line I and UAS- dHDAC6 reared on DMSO(A),
or SAHA at 150 mM (B) or 300 mM (C). Quantitation of multiple
flies reveals a significant worsening of the phenotype in flies reared
on SAHA. (* = p,0.01 compared to (CGG)90-eGFP line I alone,
+=p,0.01 compared to (CGG)90-eGFP line I x dHDAC6 by a
Students unpaired t-test).
Found at: doi:10.1371/journal.pgen.1001240.s002 (1.38 MB TIF)
Figure S3 Chromatin immunoprecipitation from pre-mutation
carrier cells. Input is crosslink reversed DNA not subjected to
immunoprecipitation. Data are expressed as a ratio to the FMR1
exon 1 signal from the input material. There is enrichment of the
FMR1 exon 1 locus in pre-mutation carrier lymphoblast cell lines
when ChIP is performed against either Ac-histone H3K9 or Ac-
histone H4 compared to IgG alone. * = P,0.001 by unpaired t-
test compared to IgG immunoprecipitation alone.
Found at: doi:10.1371/journal.pgen.1001240.s003 (0.05 MB TIF)
Figure S4 Chromatin immunoprecipitation results from each
lymphoblast cell line. ChIP was performed 3–4 times on each of 13
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different lymphoblastoid cell lines. The data from each cell line is
provided. FMR1 mRNA and ChIP results for all samples were
normalized to cell line GM20244 (CGG)41 during each qPCR run
to allow for run to run comparisons. Cell lines are divided into
normal repeat lengths (A–G), Clinically probable FXTAS patient-
derived cell lines (H,I), and pre-mutation carrier derived cell lines
whose clinical status is unknown (J–M).
Found at: doi:10.1371/journal.pgen.1001240.s004 (0.50 MB TIF)
Figure S5 Correlations between ChIP AcH3K9 and AcH4 to
CGG repeat number and FMR1 mRNA expression. For each
graph, solid black dots = control cell lines, stars = confirmed
FXTAS cases, open circles = pre-mutation carriers whose clinical
status is unknown. The central line is the linear best fit. Curved
dashed lines are 95% confidence intervals. The r2 and significance
for each correlation is shown in each graph. ChIP to Ac H3K9
correlated with CGG repeat number using PCR primers directed
at either the FMR1 promoter (Fig A, FMR1 prom AcH3K9 to
CGG#) or the FMR1 exon (Fig B, FMR1 exon AcH3K9 to
CGG#). Correlation of ChIP to Ac H3K9 and FMR1 mRNA
expression was significant using PCR primers directed at the
FMR1 exon (Fig F, FMR1 exon H3K9 to FMR1 mRNA), but not
the FMR1 promoter (Fig E, FMR1 prom AcH3K9 to FMR1
mRNA). ChIP against Ac H4 correlated with CGG repeat
number (Fig C,FMR1 prom AcH4 to CGG#; Fig D, FMR1 exon
H4 to CGG#) and FMR1 mRNA expression (Fig G, FMR1 prom
AcH4 to FMR1 mRNA; Fig H, FMR1 exon AcH4 to FMR1
mRNA) using PCR primers directed at either the FMR1 promoter
or the FMR1 first exon.
Found at: doi:10.1371/journal.pgen.1001240.s005 (0.67 MB TIF)
Figure S6 ChIP and FMR1 mRNA results from individual
fibroblast cell lines. A) ChIP against Ac H3K9 or pan acetylated
H4 and FMR1 mRNA expression normalized to Actin mRNA
expression is shown for each sell line. All data is presented as fold
change from Control fibroblast line #C1. Error bars represent SD
from 2–3 independent experiments. B–E) Correlations of individ-
ual acetylated chromatin marks as determined by ChIP (y-axis)
with CGG repeat number (x-axis). F–I) Correlation between
individual Acetylated Chromatin marks as determined by ChIP (y-
axis) with FMR1 mRNA expression (x-axis). For each, r2 and
significance of Pearson correlation is provided as an inset.
Found at: doi:10.1371/journal.pgen.1001240.s006 (0.44 MB TIF)
Figure S7 Garcinol effects on FMR1 expression are transient.
Lymphoblasts derived from a patient with probable FXTAS
(#C0014.004, CGG91 repeats) or from a control patient were
treated for 24 or 72 hours with 10 mM garcinol or DMSO. After
24 hours, some Garcinol treated cells had their media changed to
include only DMSO for 48 hours. Equal numbers of cells were
harvested and mRNA was extracted and quantified by qPCR.
FMR1 mRNA levels are normalized to 18S mRNA and expressed
(approximately) as a ratio to FMR1 expression in DMSO treated
cells. There is a significant reduction in FMR1 mRNA expression
in FXTAS cells treated for 72 hours with Garcinol, but there is no
significant difference in FMR1 expression in cells treated with
Garcinol for only 24 hours and then switched to vehicle.
*P= 0.05, Students t-test versus DMSO treated cells.
Found at: doi:10.1371/journal.pgen.1001240.s007 (0.12 MB TIF)
Figure S8 Toxic effects of HAT inhibitors on lymphoblast cells
and fly eclosion. Exposure to HAT inhibitors has been reported as
toxic to cancer cells. We therefore assessed the effects on viability
and cytotoxicity of various doses of HAT inhibitors on
lymphoblast cell lines. A) Treatment for 24 hours with garcinol
(10 mM) or anacardic acid (50 mM) at the minimally effective dose
for altering FMR1 mRNA expression did not alter cell viability. B)
However, at higher doses (20–50 mM garcinol) and with longer
exposures (48–96 hrs), these drugs were toxic to lymphoblast cell
lines. C) These drugs also blocked eclosion of flies reared on doses
greater than 25 mM. Garcinol or 75 mM anacardic acid, which
precluded performing some phenotypic rescue experiments. D)
Consistent with the decrease seen in FMR1 mRNA expression,
FMRP levels are stable after 24 hours of exposure to10 mM
garcinol but are significantly depressed after 72 hours of exposure,
although interpretation of this later time point may be complicated
by decreased cell viability (note lower molecular weight degrada-
tion products of FMRP at this time point).
Found at: doi:10.1371/journal.pgen.1001240.s008 (0.30 MB TIF)
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